JP7662644B2 - 化合物 - Google Patents
化合物 Download PDFInfo
- Publication number
- JP7662644B2 JP7662644B2 JP2022537022A JP2022537022A JP7662644B2 JP 7662644 B2 JP7662644 B2 JP 7662644B2 JP 2022537022 A JP2022537022 A JP 2022537022A JP 2022537022 A JP2022537022 A JP 2022537022A JP 7662644 B2 JP7662644 B2 JP 7662644B2
- Authority
- JP
- Japan
- Prior art keywords
- benzo
- methoxy
- ethane
- imidazole
- diyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025005355A JP2025061311A (ja) | 2019-12-18 | 2025-01-15 | 化合物 |
| JP2026073864A JP2026116400A (ja) | 2019-12-18 | 2026-04-27 | 化合物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1918761.6A GB201918761D0 (en) | 2019-12-18 | 2019-12-18 | Compounds |
| GB1918761.6 | 2019-12-18 | ||
| GB2009944.6 | 2020-06-30 | ||
| GBGB2009944.6A GB202009944D0 (en) | 2020-06-30 | 2020-06-30 | Compounds |
| PCT/AU2020/051394 WO2021119753A1 (en) | 2019-12-18 | 2020-12-18 | Compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005355A Division JP2025061311A (ja) | 2019-12-18 | 2025-01-15 | 化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506899A JP2023506899A (ja) | 2023-02-20 |
| JP2023506899A5 JP2023506899A5 (cg-RX-API-DMAC7.html) | 2023-12-12 |
| JP7662644B2 true JP7662644B2 (ja) | 2025-04-15 |
Family
ID=76476453
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537022A Active JP7662644B2 (ja) | 2019-12-18 | 2020-12-18 | 化合物 |
| JP2025005355A Pending JP2025061311A (ja) | 2019-12-18 | 2025-01-15 | 化合物 |
| JP2026073864A Pending JP2026116400A (ja) | 2019-12-18 | 2026-04-27 | 化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025005355A Pending JP2025061311A (ja) | 2019-12-18 | 2025-01-15 | 化合物 |
| JP2026073864A Pending JP2026116400A (ja) | 2019-12-18 | 2026-04-27 | 化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12415785B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4077318B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7662644B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114981265B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020409429B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3164751A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3056923T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021119753A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022266711A1 (en) * | 2021-06-23 | 2022-12-29 | Aculeus Therapeutics Pty Ltd | Substituted amidobenzimidazole dimers as sting modulators |
| CN113603661B (zh) * | 2021-08-11 | 2024-04-09 | 沈阳药科大学 | (s)-5-氟-3-甲基异苯并呋喃-3-酮的合成方法 |
| CN114349662A (zh) * | 2022-01-20 | 2022-04-15 | 杭州裕普润生物科技有限公司 | 一种溴化苄的制备方法 |
| CN114671747B (zh) * | 2022-04-08 | 2024-10-29 | 浙江永太科技股份有限公司 | 一种4-氯-2-氟苯甲醛的合成方法 |
| US20260191834A1 (en) * | 2022-11-09 | 2026-07-09 | Kathleen E. Clarence-Smith | Pharmaceutical combination for the treatment of multiple myeloma, monoclonal gammopathy of undetermined significance, and smoldering multiple myeloma |
| WO2024174863A1 (zh) * | 2023-02-22 | 2024-08-29 | 深圳众格生物科技有限公司 | Sting激动剂及其制备方法和医药用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
| JP2019510796A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | タンパク質調節因子として有用な複素環式アミド |
| WO2019134705A1 (zh) | 2018-01-08 | 2019-07-11 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2019227007A1 (en) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5414010A (en) * | 1994-05-10 | 1995-05-09 | Warner-Lambert Company | Dimeric benzimidazoles as central nervous system agents |
| US6113918A (en) | 1997-05-08 | 2000-09-05 | Ribi Immunochem Research, Inc. | Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors |
| GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| CA2310896A1 (en) | 1999-07-02 | 2001-01-02 | Japan Tobacco Inc. | Hcv polymerase suitable for crystal structure analysis and method for using the enzyme |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
| JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
| CZ20013424A3 (cs) | 1999-12-27 | 2002-02-13 | Japan Tobacco Inc. | Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva |
| PT1284740E (pt) | 2000-05-19 | 2008-07-09 | Corixa Corp | Tratamento profiláctico e terapêutico de doenças infecciosas, autoimunes e alérgicas com compostos à base de monossacáridos |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| CA2417806C (en) | 2000-08-04 | 2011-05-10 | Corixa Corporation | New immunoeffector compounds |
| US6310224B1 (en) | 2001-01-19 | 2001-10-30 | Arco Chemical Technology, L.P. | Epoxidation catalyst and process |
| MXPA03006514A (es) | 2001-01-22 | 2004-12-02 | Merck & Co Inc | Derivados de nucleosidos como inhibidores de polimerasa de acido ribonucleico viral dependiente de acido ribonucleico. |
| JP4212278B2 (ja) | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
| WO2002074769A1 (en) | 2001-03-19 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| US6911434B2 (en) | 2002-02-04 | 2005-06-28 | Corixa Corporation | Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds |
| US6525028B1 (en) | 2002-02-04 | 2003-02-25 | Corixa Corporation | Immunoeffector compounds |
| IL164376A0 (en) | 2002-04-03 | 2005-12-18 | Applied Research Systems | Ox4or binding agents, their preparation and pharmaceutical compositions containing them |
| WO2003085375A2 (en) | 2002-04-04 | 2003-10-16 | Achillion Pharmaceuticals, Inc. | Hcv antiviral and cytotoxicity drug screening assay |
| DOP2003000641A (es) | 2002-05-10 | 2003-11-15 | Pfizer | Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan |
| ES2295639T3 (es) | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| TW200418848A (en) | 2002-10-24 | 2004-10-01 | Glaxo Group Ltd | Compounds |
| DE60322423D1 (de) | 2002-12-13 | 2008-09-04 | Smithkline Beecham Corp | Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten |
| CN1744899A (zh) | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| WO2004054581A2 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Cyclohexyl compounds as ccr5 antagonists |
| WO2004055011A1 (en) | 2002-12-13 | 2004-07-01 | Smithkline Beecham Corporation | Heterocyclic compounds as ccr5 antagonists |
| ES2298627T3 (es) | 2002-12-13 | 2008-05-16 | Smithkline Beecham Corporation | Compuestos de ciclopropilo como antagonistas de ccr5. |
| EP1581530A1 (en) | 2002-12-13 | 2005-10-05 | Smithkline Beecham Corporation | Indane compounds as ccr5 antagonists |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US7960522B2 (en) | 2003-01-06 | 2011-06-14 | Corixa Corporation | Certain aminoalkyl glucosaminide phosphate compounds and their use |
| US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| US7148226B2 (en) | 2003-02-21 | 2006-12-12 | Agouron Pharmaceuticals, Inc. | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのhcvポリメラーゼ阻害剤としての利用 |
| CN1922174A (zh) | 2004-02-20 | 2007-02-28 | 贝林格尔·英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
| WO2005089777A1 (en) | 2004-03-15 | 2005-09-29 | Karaolis David K R | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis |
| EP1748991A1 (en) | 2004-04-28 | 2007-02-07 | Arrow Therapeutics Limited | Morpholinylanilinoquinazo- line derivatives for use as antiviral agents |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| ES2361845T3 (es) | 2004-08-18 | 2011-06-22 | Pfizer, Inc. | Inhibidores de arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones y tratamientos que utilizan los mismos. |
| GB0423673D0 (en) | 2004-10-25 | 2004-11-24 | Glaxo Group Ltd | Compounds |
| EP1676834A1 (en) | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| AU2006244203B2 (en) | 2005-05-09 | 2012-05-03 | Achillion Pharmaceuticals, Inc. | Thiazole compounds and methods of use |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1782826A1 (en) | 2005-11-08 | 2007-05-09 | GBF Gesellschaft für Biotechnologische Forschung mbH | PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions |
| BRPI0811466A2 (pt) | 2007-05-07 | 2014-10-14 | Medimmune Llc | Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica. |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| SI2242771T1 (sl) | 2007-12-14 | 2013-09-30 | Bristol-Myers Squibb Company | Vezane molekule k humanemu ox40 receptorju |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| WO2010056804A1 (en) | 2008-11-12 | 2010-05-20 | Medimmune, Llc | Antibody formulation |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| US20110280877A1 (en) | 2010-05-11 | 2011-11-17 | Koji Tamada | Inhibition of B7-H1/CD80 interaction and uses thereof |
| LT2609118T (lt) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| KR102023661B1 (ko) | 2011-03-31 | 2019-09-23 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Icos에 대한 항체 및 이의 용도 |
| BR112014002353B1 (pt) | 2011-08-01 | 2022-09-27 | Genentech, Inc | Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit |
| JP6038920B2 (ja) | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ox40抗体およびそれを使用する方法 |
| AU2013256468A1 (en) | 2012-04-30 | 2014-12-04 | Glen N. Barber | Modulating immune responses |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| EP2858722B8 (en) | 2012-06-08 | 2018-02-21 | Aduro BioTech, Inc. | Compostions and methods for cancer immunotherapy |
| ES2684552T3 (es) | 2012-09-03 | 2018-10-03 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| SG11201502796RA (en) | 2012-12-13 | 2015-05-28 | Aduro Biotech Inc | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
| CU24377B1 (es) | 2013-05-18 | 2018-12-05 | Aduro Biotech Inc | Dinucléotidos de purina cíclicos y composiciones de los mismos útiles para inducir la producción de interferón de tipo i dependientes de sting |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago | 癌処置としてのstingアゴニストの使用 |
| EP3152217B1 (en) | 2014-06-04 | 2018-08-01 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of sting |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
| MA53297A (fr) | 2015-03-23 | 2022-05-04 | Jounce Therapeutics Inc | Anticorps anti-icos |
| WO2017175156A1 (en) | 2016-04-07 | 2017-10-12 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides useful as protein modulators |
| JP6636673B2 (ja) | 2016-10-04 | 2020-01-29 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | STINGアゴニストとしてのベンゾ[b]チオフェン化合物 |
| CN111132972B (zh) | 2017-06-22 | 2024-07-12 | 克拉德夫制药有限公司 | 人sting的小分子调节剂 |
| JP2020524718A (ja) | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドCuradev Pharma Limited | ヒトstingの複素環式小分子調節因子 |
| US20200138827A1 (en) | 2017-06-22 | 2020-05-07 | Curadev Pharma Limited | Small molecule modulators of human sting |
| GB2563642A (en) | 2017-06-22 | 2018-12-26 | Curadev Pharma Ltd | Small molecule modulators of human STING |
| MA49772A (fr) | 2017-08-04 | 2021-04-21 | Merck Sharp & Dohme | Agonistes benzo[b]thiophène de sting pour le traitement du cancer |
| AU2018344902B2 (en) | 2017-10-05 | 2021-06-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (STING) useful in treating HIV |
| EP3755331B1 (en) | 2018-02-21 | 2026-01-28 | The Scripps Research Institute | Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer |
| US10793557B2 (en) | 2018-04-03 | 2020-10-06 | Merck Sharp & Dohme Corp. | Sting agonist compounds |
| US11702430B2 (en) | 2018-04-03 | 2023-07-18 | Merck Sharp & Dohme Llc | Aza-benzothiophene compounds as STING agonists |
| GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
-
2020
- 2020-12-18 WO PCT/AU2020/051394 patent/WO2021119753A1/en not_active Ceased
- 2020-12-18 CA CA3164751A patent/CA3164751A1/en active Pending
- 2020-12-18 ES ES20901732T patent/ES3056923T3/es active Active
- 2020-12-18 US US17/786,792 patent/US12415785B2/en active Active
- 2020-12-18 CN CN202080088737.7A patent/CN114981265B/zh active Active
- 2020-12-18 AU AU2020409429A patent/AU2020409429B2/en active Active
- 2020-12-18 EP EP20901732.6A patent/EP4077318B1/en active Active
- 2020-12-18 JP JP2022537022A patent/JP7662644B2/ja active Active
-
2025
- 2025-01-15 JP JP2025005355A patent/JP2025061311A/ja active Pending
- 2025-08-19 US US19/304,176 patent/US20260132112A1/en active Pending
-
2026
- 2026-04-27 JP JP2026073864A patent/JP2026116400A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019510796A (ja) | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | タンパク質調節因子として有用な複素環式アミド |
| WO2019069270A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | GENERATOR STIMULATOR MODULATORS (STING) INTERFERON |
| WO2019134705A1 (zh) | 2018-01-08 | 2019-07-11 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
| WO2019227007A1 (en) | 2018-05-25 | 2019-11-28 | Incyte Corporation | Tricyclic heterocyclic compounds as sting activators |
Non-Patent Citations (1)
| Title |
|---|
| Nature,2018年,564,439-443 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES3056923T3 (en) | 2026-02-25 |
| EP4077318B1 (en) | 2025-10-15 |
| US12415785B2 (en) | 2025-09-16 |
| EP4077318A1 (en) | 2022-10-26 |
| US20230062932A1 (en) | 2023-03-02 |
| CN114981265B (zh) | 2025-01-03 |
| CN114981265A (zh) | 2022-08-30 |
| WO2021119753A1 (en) | 2021-06-24 |
| CA3164751A1 (en) | 2021-06-24 |
| US20260132112A1 (en) | 2026-05-14 |
| AU2020409429B2 (en) | 2026-07-23 |
| JP2025061311A (ja) | 2025-04-10 |
| EP4077318A4 (en) | 2023-11-22 |
| AU2020409429A1 (en) | 2022-06-16 |
| JP2026116400A (ja) | 2026-07-09 |
| JP2023506899A (ja) | 2023-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3793988B1 (en) | Substituted condensed thiophenes as modulators of sting | |
| US12415785B2 (en) | Compound modulators of sting | |
| JP7607627B2 (ja) | Stingのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体 | |
| WO2022266711A1 (en) | Substituted amidobenzimidazole dimers as sting modulators | |
| JP7607626B2 (ja) | Stingのモジュレーションのためのベンゾチオフェン、チエノピリジンおよびチエノピリミジン誘導体 | |
| AU2023407213A1 (en) | Benzimidazole derivatives for the modulation of sting | |
| HK40082951A (en) | Benzimidazole dimers as modulators of sting | |
| HK40082951B (en) | Benzimidazole dimers as modulators of sting | |
| HK40049592B (en) | Substituted condensed thiophenes as modulators of sting | |
| HK40049592A (en) | Substituted condensed thiophenes as modulators of sting |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231204 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20241009 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20241015 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250115 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250305 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250403 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7662644 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |